Information Provided By: 
Fly News Breaks for July 25, 2017
GNCA
Jul 25, 2017 | 08:53 EDT
As previously reported, Needham analyst Alan Carr upgraded Genocea to Buy from Hold, with a $12 price target, after the company announced data from GEN-003 Phase 2b trial in HSV2 demonstrating durable efficacy through 12 months, and as he believes there is a "feasible" independent path to market. The analyst thinks GEN-003 is likely to be differentiated and convenient option with public health benefits.
News For GNCA From the Last 2 Days
There are no results for your query GNCA
